Back to Search
Start Over
Statistical considerations when using a composite endpoint for comparing treatment groups.
- Source :
-
Statistics in medicine [Stat Med] 2013 Feb 28; Vol. 32 (5), pp. 719-38. Date of Electronic Publication: 2012 Aug 01. - Publication Year :
- 2013
-
Abstract
- When comparing two treatment groups in a time-to-event analysis, it is common to use a composite event consisting of two or more distinct outcomes. The goal of this paper is to develop a statistical methodology to derive efficiency guidelines for deciding whether to expand a study primary endpoint from E1 (for example, non-fatal myocardial infarction and cardiovascular death) to the composite of E1 and E2 (for example, non-fatal myocardial infarction, cardiovascular death or revascularisation). We investigate this problem by considering the asymptotic relative efficiency of a log-rank test for comparing treatment groups with respect to a primary relevant endpoint E1 versus the composite primary endpoint, say E, of E1 and E2, where E2 is some additional endpoint.<br /> (Copyright © 2012 John Wiley & Sons, Ltd.)
- Subjects :
- AIDS Vaccines administration & dosage
Acute Coronary Syndrome complications
Acute Coronary Syndrome drug therapy
Acute Coronary Syndrome mortality
Anti-HIV Agents administration & dosage
Anticholesteremic Agents therapeutic use
HIV Infections drug therapy
HIV Infections immunology
Humans
Probucol analogs & derivatives
Probucol therapeutic use
Biostatistics methods
Endpoint Determination statistics & numerical data
Randomized Controlled Trials as Topic statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0258
- Volume :
- 32
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Statistics in medicine
- Publication Type :
- Academic Journal
- Accession number :
- 22855368
- Full Text :
- https://doi.org/10.1002/sim.5547